PE20061430A1 - Composicion farmaceutica que comprende compuestos de 4-quinazolinaminas - Google Patents

Composicion farmaceutica que comprende compuestos de 4-quinazolinaminas

Info

Publication number
PE20061430A1
PE20061430A1 PE2006000406A PE2006000406A PE20061430A1 PE 20061430 A1 PE20061430 A1 PE 20061430A1 PE 2006000406 A PE2006000406 A PE 2006000406A PE 2006000406 A PE2006000406 A PE 2006000406A PE 20061430 A1 PE20061430 A1 PE 20061430A1
Authority
PE
Peru
Prior art keywords
composition
weight
quinazolinamines
pharmaceutical composition
composition including
Prior art date
Application number
PE2006000406A
Other languages
English (en)
Inventor
Barry Howard Carter
Dwayne A Campbell
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061430(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of PE20061430A1 publication Critical patent/PE20061430A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA ORAL, QUE COMPRENDE: A) UN COMPUESTO DE 4-QUINAZOLINAMINAS DE FORMULA (I) DONDE R1 ES Cl o Br; X ES CH, N o CF; Het ES TIAZOL, FURANO; SIENDO PREFERIDO MONOHIDRATO DE DITOSILATO DE N-{3-CLORO-4-[(3-FLUOROBENCIL)OXI]FENIL}-6-[5-({[2-(METANOSULFONIL)ETIL]AMINO}METIL)-2-FURIL]-4-QUINAZOLAMINA (GW572016) O DENOMINADO LAPATINIB, EN UNA CANTIDAD COMPRENDIDA ENTRE 5 A 85% EN PESO DE LA COMPOSICION; B) AL MENOS UN ENLAZADOR A BASE DE GELATINA, POVIDONA, CELULOSA, ENTRE OTROS; EN UNA CANTIDAD COMPRENDIDA ENTRE 2 A 11% EN PESO DE LA COMPOSICION Y C) AL MENOS UN DESINTEGRANTE A BASE DE GLUCOLATO DE ALMIDON DE SODIO, ETILCELULOSA, BENTONITA, ENTRE OTROS; EN UNA CANTIDAD COMPRENDIDA ENTRE 1 A 10% EN PESO DE LA COMPOSICION. DICHOS COMPUESTOS SON INHIBIDORES DE CINASA DE TIROSINA DE PROTEINA EGFR Y/O erbB2, POR LO QUE SON UTILES EN EL TRATAMIENTOS DE ENFERMEDADES PROLIFERATIVAS TAL COMO CANCER DE SENO, DE PULMON, GASTRICO, ENTRE OTROS
PE2006000406A 2005-04-19 2006-04-18 Composicion farmaceutica que comprende compuestos de 4-quinazolinaminas PE20061430A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67280505P 2005-04-19 2005-04-19

Publications (1)

Publication Number Publication Date
PE20061430A1 true PE20061430A1 (es) 2007-01-25

Family

ID=37115487

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000406A PE20061430A1 (es) 2005-04-19 2006-04-18 Composicion farmaceutica que comprende compuestos de 4-quinazolinaminas

Country Status (28)

Country Link
US (3) US8821927B2 (es)
EP (1) EP1871347B1 (es)
JP (1) JP5202302B2 (es)
KR (1) KR101356748B1 (es)
CN (1) CN101203211B (es)
AR (1) AR054252A1 (es)
AU (1) AU2006236423B2 (es)
BR (1) BRPI0609962B1 (es)
CA (1) CA2606207C (es)
CY (1) CY1118179T1 (es)
DK (1) DK1871347T3 (es)
EA (1) EA200702253A1 (es)
ES (1) ES2601503T3 (es)
HR (1) HRP20161429T1 (es)
HU (1) HUE030982T2 (es)
IL (1) IL186336A0 (es)
LT (1) LT1871347T (es)
MA (1) MA29404B1 (es)
MX (1) MX2007013089A (es)
NO (1) NO20075111L (es)
NZ (1) NZ562223A (es)
PE (1) PE20061430A1 (es)
PL (1) PL1871347T3 (es)
PT (1) PT1871347T (es)
SI (1) SI1871347T1 (es)
TW (1) TW200716204A (es)
WO (1) WO2006113649A1 (es)
ZA (1) ZA200708705B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200702253A1 (ru) * 2005-04-19 2008-04-28 Смитклайн Бичем Фармацевтическая композиция
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2158913A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010099150A1 (en) * 2009-02-24 2010-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical tablet and process
WO2011039759A1 (en) * 2009-09-29 2011-04-07 Natco Pharma Limited A new process for the preparation of lapatinib and its pharmaceutically acceptable salts
JP2013526578A (ja) 2010-05-21 2013-06-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
ES2530755T3 (es) 2010-05-21 2015-03-05 Glaxosmithkline Llc Terapia de combinación para el tratamiento del cáncer
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
TW201208667A (en) 2010-08-03 2012-03-01 Altherx Inc Pharmaceutical combinations
EA029119B1 (ru) * 2013-02-19 2018-02-28 Хексаль Аг Фармацевтическая композиция, содержащая n-[3-хлор-4-(3-фторбензилокси)фенил]-6-[5({[2-(метилсульфонил)этил]амино}метил)-2-фурил]хиназолин-4-амин или его фармацевтически приемлемые соль, сольват или сольватированную соль
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
EP3226849A4 (en) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
CN106389373B (zh) * 2015-07-29 2019-07-02 四川科伦药物研究院有限公司 一种二甲苯磺酸拉帕替尼片剂及其制备方法
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法
DK3365321T3 (da) 2015-10-23 2024-01-15 B3Ar Therapeutics Inc Solabegron-zwitterion og anvendelser deraf

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
EP0977750B1 (en) 1997-04-25 2007-07-04 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
KR100850393B1 (ko) 2000-06-30 2008-08-04 글락소 그룹 리미티드 퀴나졸린 화합물의 제조방법
WO2002056912A2 (en) 2001-01-16 2002-07-25 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2003086467A1 (en) 2002-04-08 2003-10-23 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
AU2003235470A1 (en) 2002-06-19 2004-01-06 Smithkline Beecham Corporation Predictive markers in cancer therapy
EA200702253A1 (ru) * 2005-04-19 2008-04-28 Смитклайн Бичем Фармацевтическая композиция

Also Published As

Publication number Publication date
HRP20161429T1 (hr) 2016-12-16
US8821927B2 (en) 2014-09-02
ZA200708705B (en) 2009-12-30
EP1871347A1 (en) 2008-01-02
US20160143909A1 (en) 2016-05-26
LT1871347T (lt) 2016-11-10
MA29404B1 (fr) 2008-04-01
EP1871347A4 (en) 2012-10-31
TW200716204A (en) 2007-05-01
PL1871347T3 (pl) 2017-04-28
CA2606207C (en) 2014-11-18
JP5202302B2 (ja) 2013-06-05
PT1871347T (pt) 2016-11-10
KR20080005557A (ko) 2008-01-14
US20140335177A1 (en) 2014-11-13
CN101203211A (zh) 2008-06-18
IL186336A0 (en) 2008-01-20
CN101203211B (zh) 2012-08-08
BRPI0609962A2 (pt) 2011-10-11
AR054252A1 (es) 2007-06-13
CA2606207A1 (en) 2006-10-26
KR101356748B1 (ko) 2014-02-06
DK1871347T3 (en) 2016-11-28
NZ562223A (en) 2010-01-29
WO2006113649A1 (en) 2006-10-26
JP2008536931A (ja) 2008-09-11
EP1871347B1 (en) 2016-08-03
BRPI0609962B1 (pt) 2022-01-18
ES2601503T3 (es) 2017-02-15
NO20075111L (no) 2007-11-16
MX2007013089A (es) 2008-01-14
HUE030982T2 (en) 2017-06-28
EA200702253A1 (ru) 2008-04-28
SI1871347T1 (sl) 2016-11-30
CY1118179T1 (el) 2017-06-28
AU2006236423A1 (en) 2006-10-26
AU2006236423B2 (en) 2009-12-10
US20080206330A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
PE20061430A1 (es) Composicion farmaceutica que comprende compuestos de 4-quinazolinaminas
PE20080768A1 (es) Compuestos de isoindolina 5-sustituidos
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
PE20081256A1 (es) Triazalopiridacina como modulador de la actividad proteina cinasa
PE20081532A1 (es) Compuestos novedosos
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
CY1106405T1 (el) Παραγωγα κουιναζολινης
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
CY1108186T1 (el) Παραγωγα κουιναζολινης ως αναστολεις της κινασης τυροσινης
PE20040647A1 (es) Inhibidores de cinasas de tirosina
PE20060197A1 (es) Heterociclos biciclicos como inhibidores de cinasa
PE20081662A1 (es) DERIVADOS DE 6-OXO-6,7-DIHIDRO-5H-DIBENZO[b,d]AZEPIN-7-ILO
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
CY1113573T1 (el) Selurampanel
PE20080695A1 (es) Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
BRPI0507574A (pt) piridazinonas como antagonistas de alfa 4 integrinas
PE20060487A1 (es) Derivados de 2-carbamida-4-feniltiazol como moduladores de la actividad de quimioquinas
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
EA201000614A1 (ru) Производные пурина как лиганды аденозинового рецептора а
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
PE20061129A1 (es) Derivados de purina como agonistas del receptor de adenosina a2a

Legal Events

Date Code Title Description
FC Refusal